Envista Holdings Corporation (NYSE:NVST) Receives Consensus Recommendation of “Hold” from Analysts

Envista Holdings Corporation (NYSE:NVSTGet Free Report) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $20.23.

A number of research analysts have commented on the company. UBS Group decreased their price target on Envista from $21.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, May 5th. Needham & Company LLC restated a “hold” rating on shares of Envista in a research note on Thursday, March 6th. New Street Research set a $19.00 price target on Envista in a research note on Thursday, March 6th. Morgan Stanley set a $16.00 price target on Envista in a research note on Tuesday, April 15th. Finally, Baird R W upgraded Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th.

Read Our Latest Analysis on NVST

Envista Stock Up 1.4%

NYSE:NVST opened at $18.88 on Monday. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. The stock’s fifty day moving average is $17.39 and its two-hundred day moving average is $18.45. Envista has a 52 week low of $14.22 and a 52 week high of $23.00. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of -2.89, a price-to-earnings-growth ratio of 1.20 and a beta of 0.99.

Envista (NYSE:NVSTGet Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The company had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $608.17 million. During the same period in the prior year, the firm earned $0.26 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. Research analysts anticipate that Envista will post 1 EPS for the current year.

Institutional Trading of Envista

A number of large investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in Envista by 1,338.3% in the first quarter. GAMMA Investing LLC now owns 33,139 shares of the company’s stock valued at $572,000 after buying an additional 30,835 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Envista by 66.6% in the fourth quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock valued at $922,000 after buying an additional 19,100 shares during the last quarter. Comerica Bank increased its holdings in Envista by 8.2% in the fourth quarter. Comerica Bank now owns 121,851 shares of the company’s stock valued at $2,350,000 after buying an additional 9,248 shares during the last quarter. Norges Bank purchased a new position in Envista in the fourth quarter valued at $38,052,000. Finally, Natixis Advisors LLC increased its holdings in Envista by 1.8% in the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock valued at $2,057,000 after buying an additional 1,845 shares during the last quarter.

About Envista

(Get Free Report

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

Featured Stories

Analyst Recommendations for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.